Edwards to partner CardioFocus
This article was originally published in Clinica
Edwards Lifesciences is to develop and distribute products using the photonic ablation technology proprietary to CardioFocus. Under the agreement Edwards gets exclusive rights to distribute certain CardioFocus products and will collaborate in developing additional products in the field of cardiac surgery. In addition Edwards is making an equity investment in the Norton, Massachusetts-based CardioFocus.
You may also be interested in...
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.
The Trump administration says a COVID-19 vaccine could be available in as little as 12 months, but most experts think that is overpromising unless safety or efficacy standards are sacrificed. Many are urging pivotal studies that look at clinical outcomes, not surrogates, for US FDA approval.